Mitsubishi UFJ Asset Management Co. Ltd. Purchases 59,426 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,438,726 shares of the medical research company’s stock after purchasing an additional 59,426 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in IQVIA were worth $481,380,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Zions Bancorporation N.A. raised its stake in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares in the last quarter. EntryPoint Capital LLC bought a new position in IQVIA in the fourth quarter valued at about $276,000. Vanguard Group Inc. boosted its stake in shares of IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares in the last quarter. LPL Financial LLC grew its holdings in shares of IQVIA by 1.4% during the fourth quarter. LPL Financial LLC now owns 96,506 shares of the medical research company’s stock worth $18,964,000 after purchasing an additional 1,311 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $541,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 0.8 %

NYSE:IQV opened at $179.91 on Thursday. IQVIA Holdings Inc. has a one year low of $179.12 and a one year high of $253.84. The company has a market cap of $31.72 billion, a PE ratio of 23.99, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a 50-day moving average of $193.92 and a 200-day moving average of $207.10.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Barclays decreased their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Citigroup cut their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Morgan Stanley raised their price objective on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Finally, Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.